Drug Trial Radar · NCT06132932
A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations
Last checked: Nov 19, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jun 3, 2021
Primary completion
Jan 3, 2023
Study completion Jan 3, 2023
Sponsor
- Lead sponsor
- Shanghai Jiatan Pharmatech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 in patients with advanced solid tumors. The main question it aims to answer is: • safety and preliminary efficacy in WX390 therapy. Participants will be treated with WX390 orally and follow the efficacy and safety evaluation according to the protocol.
Conditions
- PIK3CA Mutation-Related Tumors
Interventions
WX390Drug
Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of WX390 in treating patients with advanced malignant solid tumors harboring PIK3CA mutations.Time frame: From the start of the trial,up to 24 weeks
- Objective Response Rate (ORR)Time frame: From the start of the trial,up to 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.